← Leaderboards
Robert C Reynolds
Southern Research Institute
$7,796,684
Attributed
$9,287,539
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2008–22$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$9,287,539 · 7
By mechanism
R01$5,896,453 · 3
P41$1,743,446 · 1
RC1$1,000,000 · 1
R21$647,640 · 2
Top collaborators
- Gary A Piazza6 shared
Most similar at Southern Research Institute
Same institution · by research overlap
- Gary A Piazza$25,461,125
- Joseph A Maddry$11,761,444
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMycobacterium TuberculosisLeadBiological AvailabilityAnalogPharmaceutical PreparationsPropertyFutureSeriesAntitubercular AgentsPharmaceutical ChemistryAmidesPathway InteractionsNovel TherapeuticsOralIn VivoMalignant NeoplasmsChronicDrug Design /Synthesis /ProductionAntineoplastic AgentsProgramsTranslationsChemical SynthesisMacrophage
Grant awards (20)
A New Paradigm for HIV Treatment: Targeted Degradation of HIV Reverse Transcriptase via the Ubiquitin-Proteasome Pathway$229,049
R21 · FY2022 · AI · contact PI
A New Paradigm for HIV Treatment: Targeted Degradation of HIV Reverse Transcriptase via the Ubiquitin-Proteasome Pathway$205,425
R21 · FY2021 · AI · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$424,008
R01 · FY2013 · CA
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$670,313
R01 · FY2012 · CA
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$569,429
R01 · FY2011 · CA
Pilot-Scale Libraries Based on Nucleoside Templates for the ML Initiative$581,208
P41 · FY2010 · GM · contact PI
Targeting MDR-TB$500,000
RC1 · FY2010 · AI · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$1
R01 · FY2010 · CA
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$674,075
R01 · FY2009 · CA
Pilot-Scale Libraries Based on Nucleoside Templates for the ML Initiative$581,148
P41 · FY2009 · GM · contact PI
Targeting MDR-TB$500,000
RC1 · FY2009 · AI · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$643,885
R01 · FY2008 · CA
Pilot-Scale Libraries Based on Nucleoside Templates for the ML Initiative$581,090
P41 · FY2008 · GM · contact PI
Inhibitor of FtsZ Polymerization in M. tuberculosis$551,207
R01 · FY2004 · AI
Inhibitor of FtsZ Polymerization in M. tuberculosis$551,207
R01 · FY2003 · AI
Inhibitor of FtsZ Polymerization in M. tuberculosis$551,207
R01 · FY2002 · AI
GLYCOSYLTRANSFERASES AS DRUG TARGETS IN MYCOBACTERIA$431,232
R01 · FY2002 · AI
Crystallization of the Galactosyltransferase from Mtb$213,166
R21 · FY2002 · AI
GLYCOSYLTRANSFERASES AS DRUG TARGETS IN MYCOBACTERIA$420,267
R01 · FY2001 · AI
GLYCOSYLTRANSFERASES AS DRUG TARGETS IN MYCOBACTERIA$409,622
R01 · FY2000 · AI